If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
In another one-pot multicomponent reaction, a unique two-carbon expansion has been achieved by reacting isatin with indene-1,3-dione and N-substituted pyridinium bromide to form dibenzo[b,d]azepin-6-ones.
=== Management === Various methods can be used to manage backup media, striking a balance between accessibility, security and cost. These media management methods are not mutually exclusive and are frequently combined to meet the user's needs. Using on-line disks for staging data before it is sent to a near-line tape library is a common example.
==== Fuel cells ==== Appropriately perforated graphene (and hexagonal boron nitride hBN) can allow protons to pass through it, offering the potential for using graphene monolayers as a barrier that blocks hydrogen atoms but not protons/ionized hydrogen (hydrogen atoms with their electrons stripped off). They could even be used to extract hydrogen gas out of the atmosphere that could power electric generators with ambient air. The membranes are more effective at elevated temperatures and when covered with catalytic nanoparticles such as platinum. Graphene could solve a major problem for fuel cells: fuel crossover that reduces efficiency and durability. In methanol fuel cells, graphene used as a barrier layer in the membrane area, has reduced fuel cross over with negligible proton resistance, improving the performance. At room temperature, proton conductivity with monolayer hBN, outperforms graphene, with resistivity to proton flow of about 10 Ω cm2 and a low activation energy of about 0.3 electronvolts. At higher temperatures, graphene outperforms with resistivity estimated to fall below 10−3 Ω cm2 above 250 degrees Celsius. In another project, protons easily pass through slightly imperfect graphene membranes on fused silica in water. The membrane was exposed to cycles of high and low pH. Protons transferred reversibly from the aqueous phase through the graphene to the other side where they undergo acid–base chemistry with silica hydroxyl groups.
Sources: en.wikipedia.org
== Reaction == The journalist David Miller, writing for The Times, described Cambridge's victory as "crushingly conclusive". Cambridge's Malcolm Baker said: "We knew we could do it after about 25 strokes." Behrens explained "Our strength was that we were more uniform than Oxford. We have proved that you do not have to be an Olympic champion to win the Boat Race." The Oxford Boat Club president Pinsent conceded: "They put right a lot of mistakes they have made in the past, and they rowed outstandingly well." Spracklen agreed: "Cambridge got too far away. They were a better boat in that race. All credit to them." Cambridge's number two, David Gillard, said "there was a lot of revenge out there". Writing in The Independent, the journalist Chris Arnot noted that the Cambridge crew had used creatine supplements in order to attempt to enhance their performance. Used extensively at the 1992 Olympics, by athletes including Linford Christie and Sally Gunnell, and given to horses and greyhounds, creatine was believed to provide legal energy-enhancing effects to the crew.
Dense irregular connective tissue is a form of dense connective tissue characterized by collagen fibers that appear randomly interwoven instead of forming parallel bundles as in dense regular connective tissue. Dense irregular connective tissue has less ground substance than loose connective tissue. Fibroblasts are the predominant cell type, scattered sparsely across the tissue.
zone melting Any of several methods of purifying crystalline solids which involve applying heat to a small region of a larger solid (particularly a metal ingot) until localized melting occurs, creating a molten zone which is then slowly moved along the surface to other parts of the solid by moving the target of the heating element. As it moves, the forward edge of the molten zone continuously melts new areas of impure solid, while leaving a path of purer solid behind it as previously melted areas are cooled and resolidified; because the molten liquid phase can hold a higher concentration of impurities than the solid phase, the impurities of melted areas tend to concentrate in the molten zone and be carried along as it moves, leaving behind regions with fewer impurities. The process is commonly used in the refinement of high-purity metalloids for use in semiconductors.
The cyclol model was consistent with the general properties then attributed to folded proteins. (1) Centrifugation studies had shown that folded proteins were significantly denser than water (~1.4 g/mL) and, thus, tightly packed; Wrinch assumed that dense packing should imply regular packing. (2) Despite their large size, some proteins crystallize readily into symmetric crystals, consistent with the idea of symmetric faces that match up upon association. (3) Proteins bind metal ions; since metal-binding sites must have specific bond geometries (e.g., octahedral), it was plausible to assume that the entire protein also had similarly crystalline geometry. (4) As described above, the cyclol model provided a simple chemical explanation of denaturation and the difficulty of cleaving folded proteins with proteases. (5) Proteins were assumed to be responsible for the synthesis of all biological molecules, including other proteins. Wrinch noted that a fixed, uniform structure would be useful for proteins in templating their own synthesis, analogous to the Watson-Francis Crick concept of DNA templating its own replication. Given that many biological molecules such as sugars and sterols have a hexagonal structure, it was plausible to assume that their synthesizing proteins likewise had a hexagonal structure. Wrinch summarized her model and the supporting molecular-weight experimental data in three review articles.
Sources: en.wikipedia.org
One aptamer, in particular, proved effective as a recognition element in an electrochemical sensor, enabling the detection of sGP and GP1.2 in solution, as well as GP1.2 within a membrane context. The results of this research point to the intriguing possibility that certain regions on protein surfaces may possess aptatropic qualities. Identifying the key features of such sites, in conjunction with improved 3-D structural predictions for aptamers, holds the potential to enhance the accuracy of predicting aptamer interaction sites on proteins. This, in turn, may help identify aptamers with a heightened likelihood of binding proteins with high affinity, as well as shed light on protein mutations that could significantly impact aptamer binding. This comprehensive understanding of the structure-based interactions between aptamers and proteins is vital for refining the computational predictability of aptamer-protein binding. Moreover, it has the potential to eventually eliminate the need for the experimental SELEX protocol.
=== Women === Hyperandrogenism, especially high levels of testosterone, can cause serious adverse effects if left untreated. High testosterone levels are associated with other health conditions such as obesity, hypertension, amenorrhea (cessation of menstrual cycles), and ovulatory dysfunction, which can lead to infertility. Prominent signs of hyperandrogenism are hirsutism (unwanted growth of hair, especially in the abdominal region and on the back), adult acne, deepening of the voice, and alopecia (balding). Hyperandrogenism has also been observed to increase insulin tolerance, which can lead to type two diabetes and dyslipidemia, such as high cholesterol. These effects may have psychological impacts, sometimes leading to social anxiety and depression, especially in adolescent girls and young women. Paired with obesity and hirsutism, it can cause the individual to have low self-esteem.
=== EC 1.1.98 With other, known, acceptors === EC 1.1.98.1: Now EC 1.1.9.1, alcohol dehydrogenase (azurin) EC 1.1.98.2: glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.98.3: decaprenylphospho-β-D-ribofuranose 2-oxidase EC 1.1.98.3: decaprenylphospho-β-D-ribofuranose 2-dehydrogenase EC 1.1.98.4: F420H2:quinone oxidoreductase EC 1.1.98.5: secondary-alcohol dehydrogenase (coenzyme-F420) EC 1.1.98.6: ribonucleoside-triphosphate reductase (formate) EC 1.1.98.7: serine-type anaerobic sulfatase-maturating enzyme
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.